Biolinerx Ltd. revenue

Biolinerx Ltd.'s revenue was $1.2m in fiscal 2025, down 95.9% on the year before.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Biolinerx Ltd.: revenue history, annual
Fiscal year	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	0	0	5	29	1
Growth on the year before	—	—	—	+502.9%	−95.9%
Gross profit	0	0	1	20	1
Gross margin	—	—	23.1%	68.0%	80.5%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Biolinerx Ltd.	$1.2m	-95.9%	—
Longeveron Inc.	$1.2m	-42.7%	10.4%
Dare Bioscience, Inc.	$1.4m	4366.5%	—
Shattuck Labs, Inc.	$1.0m	-66.6%	5.2%
Cartesian Therapeutics, Inc.	$1.5m	44.0%	-68.8%
Medicinova Inc	$920,481	875.7%	—

Compare with peers

Head to head: BLRX vs LGVN BLRX vs DARE BLRX vs STTK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Biolinerx Ltd.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biolinerx Ltd.